Barriers to genomic testing reduce clinical trial eligibility for diverse populations

被引：0
|
作者：
McCleary, Nadine J.
机构：
来源：
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | 2024年 / 33卷 / 09期
关键词：
D O I：
10.1158/1538-7755.DISP24-C070
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C070
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Clinical Trial Access in Diverse Populations
    Montaque, Tareefe
    Stewart, John
    JOURNAL OF SURGICAL ONCOLOGY, 2024,
  • [2] Enrollment of Diverse Populations in the INGENIOUS Pharmacogenetics Clinical Trial
    Shah-Williams, Ebony
    Levy, Kenneth D.
    Zang, Yong
    Holmes, Ann M.
    Stoughton, Christa
    Dexter, Paul
    Skaar, Todd C.
    FRONTIERS IN GENETICS, 2020, 11
  • [3] Implementing genomic screening in diverse populations
    Abul-Husn, Noura S.
    Soper, Emily R.
    Braganza, Giovanna T.
    Rodriguez, Jessica E.
    Zeid, Natasha
    Cullina, Sinead
    Bobo, Dean
    Moscati, Arden
    Merkelson, Amanda
    Loos, Ruth J. F.
    Cho, Judy H.
    Belbin, Gillian M.
    Suckiel, Sabrina A.
    Kenny, Eimear E.
    GENOME MEDICINE, 2021, 13 (01)
  • [4] Implementing genomic screening in diverse populations
    Noura S. Abul-Husn
    Emily R. Soper
    Giovanna T. Braganza
    Jessica E. Rodriguez
    Natasha Zeid
    Sinead Cullina
    Dean Bobo
    Arden Moscati
    Amanda Merkelson
    Ruth J. F. Loos
    Judy H. Cho
    Gillian M. Belbin
    Sabrina A. Suckiel
    Eimear E. Kenny
    Genome Medicine, 13
  • [5] Barriers to eligibility and enrollment among older women in a clinical trial on osteoporosis: Effects of ethnicity and SES
    Unson, CG
    Ohannessian, C
    Kenyon, L
    Case, A
    Reisine, S
    Prestwood, K
    JOURNAL OF AGING AND HEALTH, 2004, 16 (03) : 426 - 443
  • [6] Genomic and epigenomic studies of cholangiocarcinoma in diverse populations
    Teh, Bin Tean
    CANCER RESEARCH, 2019, 79 (13)
  • [7] Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
    Huebner, Hanna
    Kurbacher, Christian M.
    Kuesters, Geoffrey
    Hartkopf, Andreas D.
    Lux, Michael P.
    Huober, Jens
    Volz, Bernhard
    Taran, Florin-Andrei
    Overkamp, Friedrich
    Tesch, Hans
    Haeberle, Lothar
    Lueftner, Diana
    Wallwiener, Markus
    Mueller, Volkmar
    Beckmann, Matthias W.
    Belleville, Erik
    Ruebner, Matthias
    Untch, Michael
    Fasching, Peter A.
    Janni, Wolfgang
    Fehm, Tanja N.
    Kolberg, Hans-Christian
    Wallwiener, Diethelm
    Brucker, Sara Y.
    Schneeweiss, Andreas
    Ettl, Johannes
    BMC CANCER, 2020, 20 (01)
  • [8] Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
    Hanna Huebner
    Christian M. Kurbacher
    Geoffrey Kuesters
    Andreas D. Hartkopf
    Michael P. Lux
    Jens Huober
    Bernhard Volz
    Florin-Andrei Taran
    Friedrich Overkamp
    Hans Tesch
    Lothar Häberle
    Diana Lüftner
    Markus Wallwiener
    Volkmar Müller
    Matthias W. Beckmann
    Erik Belleville
    Matthias Ruebner
    Michael Untch
    Peter A. Fasching
    Wolfgang Janni
    Tanja N. Fehm
    Hans-Christian Kolberg
    Diethelm Wallwiener
    Sara Y. Brucker
    Andreas Schneeweiss
    Johannes Ettl
    BMC Cancer, 20
  • [9] The patient experience: Clinical trial knowledge, attitudes and participation among diverse populations
    Strom, Carla
    Winkfield, Karen M.
    Tooze, Janet A.
    Ruiz, Jimmy
    Shore, Kelsey
    Weaver, Kathryn E.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2020, 29 (06)
  • [10] Clinical Trial Inclusion and Impact on Early Adoption of Medical Innovation in Diverse Populations
    Adamson, Philip B.
    Echols, Melvin
    Defilippis, Ersilia M.
    Morris, Alanna A.
    Bennett, Mosi
    Abraham, William T.
    Lindenfeld, Joann
    Teerlink, John R.
    Connor, Christopher M. O. '
    Connolly, Allison T.
    Li, Huanan
    Fiuzat, Mona
    Vaduganathan, Muthiah
    Vardeny, Orly
    Batchelor, Wayne
    Mccants, Kelly C.
    JACC-HEART FAILURE, 2024, 12 (07) : 1212 - 1222
12345